Grufity logoGrufity logo
Stocks
Funds
Screener
Sectors
Watchlists
SGHT

SGHT - Sight Sciences, Inc. Stock Price, Fair Value and News

$6.03+0.01 (+0.17%)
Market Closed

15/100

SGHT

STOCK SCORE

High Scoring Large Cap stocks have outperformed low scoring stocks by 90% over last 10 years

15/100

SGHT

STOCK SCORE

High Scoring Large Cap stocks have outperformed low scoring stocks by 90% over last 10 years

Price Targets

Target 1Y

$4.82

Target 3M

$5.42

Target 6M

$5.12

SGHT Stock Valuation Analysis

Valuation

Login to View

Max Portfolio %

Login to View

SGHT Price Action

Last 7 days

-5.5%

Last 30 days

-30.2%

Last 90 days

18.7%

Trailing 12 Months

92.7%

SGHT RSI Chart

SGHT Stock Valuation Analysis

Valuation

Login to View

Max Portfolio %

Login to View

SGHT Valuation

Market Cap

318.8M

Price/Earnings (Trailing)

-6.91

Price/Sales (Trailing)

4.19

EV/EBITDA

-6.58

Price/Free Cashflow

-10.01

SGHT Price/Sales (Trailing)

The Good, Bad and Ugly

Growth

Profitability

Size

Dilution Risk

Balance Sheet

Momentum

Funds Popularity

Insider Trading

Price Targets

Target 1Y

$4.82

Target 3M

$5.42

Target 6M

$5.12

SGHT Fundamentals

SGHT Revenue

Revenue (TTM)

76.1M

Rev. Growth (Yr)

-1.25%

Rev. Growth (Qtr)

1.75%

SGHT Earnings

Earnings (TTM)

-46.1M

Earnings Growth (Yr)

26.18%

Earnings Growth (Qtr)

31.59%

SGHT Profitability

EBT Margin

-60.58%

Return on Equity

-71.72%

Return on Assets

-39.66%

Free Cashflow Yield

-9.99%

SGHT Investor Care

Shares Dilution (1Y)

4.17%

Diluted EPS (TTM)

-0.9

SGHT Alerts

  • 1 major insider sales recently.

Historical Charts for Stock Metrics

Get all data in R, Python etc through our Historical Stock Data APIs
Net sales
YearQ1Q2Q3Q4
202578.1M76.3M76.1M0
202481.5M79.4M79.5M79.9M
202375.3M81.5M82.8M81.1M
202255.2M59.9M65.5M71.3M
202133.0M38.3M43.6M49.0M
202000027.6M
Get all data in R, Python etc through our Historical Stock Data APIs

About Sight Sciences, Inc.

SGHT
Sight Sciences, Inc., an ophthalmic medical device company, engages in the development and commercialization of surgical and nonsurgical technologies for the treatment of eye diseases. The company's products include OMNI Surgical System, a therapeutic device used by ophthalmic surgeons to reduce intraocular pressure in adult glaucoma patients; and TearCare System, a wearable eyelid technology for the treatment of dry eye disease (DED) for ophthalmologists and optometrists. It offers its products through sales representatives and distributors to hospitals, medical centers, and eyecare professionals in the United States. Sight Sciences, Inc. was incorporated in 2010 and is headquartered in Menlo Park, California.
 CEO
 WEBSITEsightsciences.com
 SECTORHealthcare
 INDUSTRYMedical Devices
 EMPLOYEES250

Sight Sciences, Inc. Frequently Asked Questions

SGHT is the stock ticker symbol of Sight Sciences, Inc.. Every public company that trades on a stock exchange gets a ticker symbol.

As of Wed Jan 28 2026, market cap of Sight Sciences, Inc. is 318.82 Million. The market capitalization is calculated by multiplying the stock price with the number of shares outstanding.

You can check SGHT's fair value in chart for subscribers.

The fair value guage provides a quick view whether SGHT is over valued or under valued. Whether Sight Sciences, Inc. is cheap or expensive depends on the assumptions which impact Sight Sciences, Inc.'s fair value. We provide several scenarios of inflation and growth to encompass these range of assumptions for SGHT.

As of Wed Jan 28 2026, SGHT's PE ratio (Price to Earnings) is -6.91 and Price to Sales (PS) ratio is 4.19. The price to earnings and price to sales ratio are two most important valuation metrics for any company. PE ratio tell us the number of years of earnings investors are ready to pay for owning the company. Historically, S&P500 price to earnings ratio has fallen below 12 during periods of gloom and gone past 30 during periods of euphoria. SGHT PE ratio will change depending on the future growth rate expectations of investors.